Updated data across two dose levels of 200 mW/cm and 400 mW/cm in LA-PDAC trial show 71% (5/7) patients resected following VTP with a consistent and well-tolerated safety profile Early clinical observations of Padeliporfin VTP in LA-PDAC support advancement of the program with potential for accelerated registrational pathway, strengthened by robust efficacy and durability data … Continued

Complete response (CR) observed in 70% (50/72) of evaluable patients with low-grade upper tract urothelial cancer (UTUC) who completed Primary Response Evaluation (PRE) Updated durability data shows 85.7% (18/21) of patients who completed the Maintenance Treatment Phase (MTP) sustained CRs in the treated area for at least 12 months as of the data cutoff date … Continued

Company to present updated data from the Phase 3 ENLIGHTED trial of Padeliporn VTP in LG UTUC with topline data expected in 2026 Additional preliminary data from the Phase 1 trial in LA-PDAC to be presented at ASCO; initial data from rst cohort show promising signs of efcacy with a well-tolerated safety prole   TEL … Continued

Initial data from first cohort in LA-PDAC show 66% (2/3) patients resected following VTP at lowest light dose with a consistent and well-tolerated safety profile LA-PDAC program represents large market opportunity in highest unmet need patients, with potential for accelerated registrational pathway; additional results from Phase 1 trial expected in 2026 Topline data from Phase … Continued

Complete response (CR) observed in 70% (35/50) of patients with low-grade upper tract urothelial cancer (UTUC) who completed the Induction Treatment Phase (ITP) Initial durability data shows all patients (100%) who completed the Maintenance Treatment Phase (MTP) sustained CRs in the treated area for at least 12 months as of the data cutoff date Padeliporfin … Continued